Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Aug;74(4):579–584. doi: 10.1038/bjc.1996.404

Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence.

T R Griffiths 1, I Brotherick 1, R I Bishop 1, M D White 1, D M McKenna 1, C H Horne 1, B K Shenton 1, D E Neal 1, J K Mellon 1
PMCID: PMC2074678  PMID: 8761373

Abstract

Sera from 40 patients with newly diagnosed bladder cancer (28 superficial tumours (pTa and pT1) and 12 muscle-invasive tumours) were assessed by enzyme-linked immunosorbent assay (ELISA) to determine the concentrations of soluble E-cadherin (sE-cadherin), soluble E-selectin (sE-selectin), soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1 (sICAM-1). Corresponding frozen sections of primary tumour were analysed for E-cadherin expression using the monoclonal antibody, HECD-1 and standard immunohistochemistry. Patients with bladder cancer had significantly higher concentrations of sE-cadherin compared with a control group (P = 0.017). No difference was found between the two groups with regard to sE-selection (P = 0.403), sVCAM-1 (P = 0.942) and sICAM-1 (P = 0.092). High levels of sE-cadherin were related to poor histological grade (P = 0.009), number of superficial tumours at presentation (P = 0.008) and a positive 3 month check cytoscopy in superficial disease (P = 0.036). Abnormal E-cadherin expression was associated with increasing tumour stage (P = 0.009) and grade (P = 0.03). There was no correlation between high levels of soluble E-cadherin in sera and abnormal E-cadherin expression by the tumour (P = 0.077). Elevated levels of sE-cadherin are found in sera of patients with bladder cancer and correlate with known prognostic factors.

Full text

PDF
579

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Althausen A. F., Prout G. R., Jr, Daly J. J. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol. 1976 Nov;116(5):575–580. doi: 10.1016/s0022-5347(17)58916-8. [DOI] [PubMed] [Google Scholar]
  2. Banks R. E., Gearing A. J., Hemingway I. K., Norfolk D. R., Perren T. J., Selby P. J. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer. 1993 Jul;68(1):122–124. doi: 10.1038/bjc.1993.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Banks R. E., Porter W. H., Whelan P., Smith P. H., Selby P. J. Soluble forms of the adhesion molecule E-cadherin in urine. J Clin Pathol. 1995 Feb;48(2):179–180. doi: 10.1136/jcp.48.2.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Becker J. C., Dummer R., Schwinn A., Hartmann A. A., Burg G. Circulating intercellular adhesion molecule-1 in melanoma patients: induction by interleukin-2 therapy. J Immunother (1991) 1992 Aug;12(2):147–150. doi: 10.1097/00002371-199208000-00010. [DOI] [PubMed] [Google Scholar]
  5. Behrens J., Birchmeier W., Goodman S. L., Imhof B. A. Dissociation of Madin-Darby canine kidney epithelial cells by the monoclonal antibody anti-arc-1: mechanistic aspects and identification of the antigen as a component related to uvomorulin. J Cell Biol. 1985 Oct;101(4):1307–1315. doi: 10.1083/jcb.101.4.1307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bringuier P. P., Umbas R., Schaafsma H. E., Karthaus H. F., Debruyne F. M., Schalken J. A. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 1993 Jul 15;53(14):3241–3245. [PubMed] [Google Scholar]
  7. Greene L. F., Hanash K. A., Farrow G. M. Benign papilloma or papillary carcinoma of the bladder? J Urol. 1973 Aug;110(2):205–207. doi: 10.1016/s0022-5347(17)60161-7. [DOI] [PubMed] [Google Scholar]
  8. Harning R., Mainolfi E., Bystryn J. C., Henn M., Merluzzi V. J., Rothlein R. Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res. 1991 Sep 15;51(18):5003–5005. [PubMed] [Google Scholar]
  9. Katayama M., Hirai S., Kamihagi K., Nakagawa K., Yasumoto M., Kato I. Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer. 1994 Mar;69(3):580–585. doi: 10.1038/bjc.1994.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Koch A. E., Halloran M. M., Haskell C. J., Shah M. R., Polverini P. J. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature. 1995 Aug 10;376(6540):517–519. doi: 10.1038/376517a0. [DOI] [PubMed] [Google Scholar]
  11. Lipponen P. K., Eskelinen M. J. Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol. 1995;121(5):303–308. doi: 10.1007/BF01209598. [DOI] [PubMed] [Google Scholar]
  12. Lunec J., Challen C., Wright C., Mellon K., Neal D. E. c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder. Lancet. 1992 Feb 15;339(8790):439–440. doi: 10.1016/0140-6736(92)90135-p. [DOI] [PubMed] [Google Scholar]
  13. Lutzeyer W., Rübben H., Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol. 1982 Feb;127(2):250–252. doi: 10.1016/s0022-5347(17)53725-8. [DOI] [PubMed] [Google Scholar]
  14. Mostofi F. K. International histologic classification of tumors. A report by the Executive Committee of the International Council of Societies of Pathology. Cancer. 1974 May;33(5):1480–1484. doi: 10.1002/1097-0142(197405)33:5<1480::aid-cncr2820330536>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  15. Nagafuchi A., Takeichi M. Cell binding function of E-cadherin is regulated by the cytoplasmic domain. EMBO J. 1988 Dec 1;7(12):3679–3684. doi: 10.1002/j.1460-2075.1988.tb03249.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Natali P., Nicotra M. R., Cavaliere R., Bigotti A., Romano G., Temponi M., Ferrone S. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res. 1990 Feb 15;50(4):1271–1278. [PubMed] [Google Scholar]
  17. Oosterlinck W., Kurth K. H., Schröder F., Bultinck J., Hammond B., Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993 Apr;149(4):749–752. doi: 10.1016/s0022-5347(17)36198-0. [DOI] [PubMed] [Google Scholar]
  18. Otto T., Birchmeier W., Schmidt U., Hinke A., Schipper J., Rübben H., Raz A. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res. 1994 Jun 15;54(12):3120–3123. [PubMed] [Google Scholar]
  19. Parmar M. K., Freedman L. S., Hargreave T. B., Tolley D. A. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol. 1989 Aug;142(2 Pt 1):284–288. doi: 10.1016/s0022-5347(17)38731-1. [DOI] [PubMed] [Google Scholar]
  20. Reading J., Hall R. R., Parmar M. K. The application of a prognostic factor analysis for Ta.T1 bladder cancer in routine urological practice. Br J Urol. 1995 May;75(5):604–607. doi: 10.1111/j.1464-410x.1995.tb07417.x. [DOI] [PubMed] [Google Scholar]
  21. Rebel J. M., Thijssen C. D., Vermey M., Delouvée A., Zwarthoff E. C., Van der Kwast T. H. E-cadherin expression determines the mode of replacement of normal urothelium by human bladder carcinoma cells. Cancer Res. 1994 Oct 15;54(20):5488–5492. [PubMed] [Google Scholar]
  22. Rice G. E., Bevilacqua M. P. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science. 1989 Dec 8;246(4935):1303–1306. doi: 10.1126/science.2588007. [DOI] [PubMed] [Google Scholar]
  23. Shimoyama Y., Hirohashi S., Hirano S., Noguchi M., Shimosato Y., Takeichi M., Abe O. Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. Cancer Res. 1989 Apr 15;49(8):2128–2133. [PubMed] [Google Scholar]
  24. Sidransky D., Frost P., Von Eschenbach A., Oyasu R., Preisinger A. C., Vogelstein B. Clonal origin bladder cancer. N Engl J Med. 1992 Mar 12;326(11):737–740. doi: 10.1056/NEJM199203123261104. [DOI] [PubMed] [Google Scholar]
  25. Smith G., Elton R. A., Chisholm G. D., Newsam J. E., Hargreave T. B. Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases. Br J Urol. 1986 Dec;58(6):659–663. doi: 10.1111/j.1464-410x.1986.tb05907.x. [DOI] [PubMed] [Google Scholar]
  26. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 1991 Mar 22;251(5000):1451–1455. doi: 10.1126/science.2006419. [DOI] [PubMed] [Google Scholar]
  27. Tolley D. A., Hargreave T. B., Smith P. H., Williams J. L., Grigor K. M., Parmar M. K., Freedman L. S., Uscinska B. M. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J (Clin Res Ed) 1988 Jun 25;296(6639):1759–1761. doi: 10.1136/bmj.296.6639.1759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Umbas R., Schalken J. A., Aalders T. W., Carter B. S., Karthaus H. F., Schaafsma H. E., Debruyne F. M., Isaacs W. B. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 1992 Sep 15;52(18):5104–5109. [PubMed] [Google Scholar]
  29. Wheelock M. J., Buck C. A., Bechtol K. B., Damsky C. H. Soluble 80-kd fragment of cell-CAM 120/80 disrupts cell-cell adhesion. J Cell Biochem. 1987 Jul;34(3):187–202. doi: 10.1002/jcb.240340305. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES